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Abstract
Regulation of PCNA ubiquitylation plays a key role in the tolerance to DNA damage in eukaryotes. Although the
evolutionary conserved mechanism of PCNA ubiquitylation is well understood, the deubiquitylation of ubPCNA remains
poorly characterized. Here, we show that the histone H2BK123 ubiquitin protease Ubp10 also deubiquitylates ubPCNA in
Saccharomyces cerevisiae. Our results sustain that Ubp10-dependent deubiquitylation of the sliding clamp PCNA normally
takes place during S phase, likely in response to the simple presence of ubPCNA. In agreement with this, we show that
Ubp10 forms a complex with PCNA in vivo. Interestingly, we also show that deletion of UBP10 alters in different ways the
interaction of PCNA with DNA polymerase f–associated protein Rev1 and with accessory subunit Rev7. While deletion of
UBP10 enhances PCNA–Rev1 interaction, it decreases significantly Rev7 binding to the sliding clamp. Finally, we report that
Ubp10 counteracts Rad18 E3-ubiquitin ligase activity on PCNA at lysine 164 in such a manner that deregulation of Ubp10
expression causes tolerance impairment and MMS hypersensitivity.
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Introduction
In living cells, tolerance mechanisms ensure that DNA can be
replicated when it is damaged. These mechanisms prevent
irreversible DNA replication fork collapse when the replisome
encounters bulky lesions at damaged sites that block progression of
replicative DNA polymerases [1,2]. DNA lesions are bypassed
either by a mechanism involving low stringency DNA polymerases
called translesion synthesis (TLS) polymerases or by promoting
template-switching between nascent chains within the same
replication fork [2–6]. It is thought that both mechanisms
efficiently prevent replisome stalling at damaged sites. The use
of TLS polymerases may be mutagenic because they induce an
error-prone process that causes damaged-dependent mutations.
However, it has been shown that in yeast ultraviolet-radiation-
induced DNA lesions are predominantly bypassed via translesion
synthesis [7].
Eukaryotes ubiquitylate proliferating-cell nuclear antigen
(PCNA) to signal damaged DNA and regulate the choice of
alternative pathways to bypass DNA lesions during S-phase,
therefore, to tolerate DNA damage [2–6]. The sliding clamp
PCNA is monoubiquitylated at Lys164 by the Rad6-Rad18 (E2–
E3) ubiquitin ligase complex in response to endogenous or
exogenous damage causing disruptive covalent modifications of
DNA interfering with high-fidelity replicative polymerases during
S phase. Mono-ubiquitylated PCNA (ubPCNA) enhances the
affinity of error-prone TLS DNA polymerases which facilitate
translesion synthesis bypass. Then, the Mms2-Ubc13-Rad5
ubiquitin ligase complex may further ubiquitylate Lys164-mono-
ubiquitylated PCNA to promote template switching, the error-free
component of the bypass that involves sister-strand pairing [5,8]
and references therein). This regulatory mechanism based on
covalent modifications of the Lys164 of the sliding clamp PCNA is
a solidly established model conserved in all eukaryotes [2–5,9].
Ubiquitylation of Lys164-PCNA (ubPCNA) greatly enhances
binding of the sliding clamp with TLS polymerases [10]. In
contrast with replicative enzymes, TLS polymerases are low
fidelity DNA polymerases, non-processive enzymes that lack any
proofreading activity but capable of replicating over DNA lesions
[11] (and references there in). Indeed, TLS polymerases are DNA
damage-tolerant enzymes but also mutagenic because they may
incorporate mispaired deoxynucleotides opposite to lesions (dam-
aged template) in an error-prone process [12,13] (and references
there in). Because of their low fidelity and low processivity when
incorporating deoxynucleotides across from damaged and un-
damaged base pairs [12,14–17], cells need to keep TLS DNA
polymerases from sampling replicative DNA more that strictly
required and/or to prevent them from extended interaction with
replication forks. Therefore, cells may need a control mechanism
to deubiquitylate ubPCNA as soon as TLS DNA polymerases have
been able to replicate over the damaged site.
Human Usp1 has been identified as a protease that deubiqui-
tylates mono-ubPCNA [18]. Upon UV-light induced DNA
damage, Usp1 is degraded so that PCNA becomes ubiquitylated
[18,19], suggesting that Usp1 deubiquitylates PCNA continuously
in the absence of DNA damage [18]. However, accumulation of
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ubPCNA does not correlate with Usp1 proteolysis when the
progression of replication forks is stalled with HU [20], suggesting
either a complex regulation of Usp1 activity (or its subcellular
localization) when cells are exposed to other DNA damaging
agents or the existence of at least one another PCNA
deubiquitylating enzyme in mammals acting in response to other
DNA damaging agents. Despite the identification of Usp1, little is
known about the deubiquitylation of ubPCNA in any other
organism.
In Saccharomyces cerevisiae, the protease (or proteases) that
deubiquitylates ubPCNA remains unknown. Potential candidates
in budding yeast are 17 genes that codify for different ubiquitin-
specific proteases. Few of them have been extensively studied while
others remain poorly characterized [21–23]. These genes are
named UBPs (from UBP1 to UBP17), where UBP stands for
ubiquitin protease. Among the ubiquitin-specifc proteases charac-
terized, Ubp10/Dot4 is remarkable; this is a deubiquitylating
enzyme related to gene-silencing that regulates histone ubH2B
deubiquitylation and helps to localise the histone deacetylase Sir2
complex at telomeres, cryptic mating type loci (HML and HMR)
and rDNA loci [24,25]. Here we describe a new role for Ubp10 in
deubiquitylating the sliding clamp ubPCNA. We performed a
biochemical screening with yeast UBPs single mutants to identify
ubiquitin proteases that might play a role in the reversal of PCNA
ubiquitylation and found that UBP10 mutants accumulate
ubiquitylated forms of PCNA. Consistent with a direct role in
ubPCNA deubiquitylation, we found that catalyticaly active
Ubp10 reverts PCNA ubiquitylation.
Results
A biochemical screening identifies Ubp10/Dot4 as a
potential DUB for PCNA
In yeast, the ubiquitylation of PCNA might be a reversible
process catalyzed by deubiquitylating enzymes (or DUBs).
Sequence and functional analyses have revealed that in budding
yeast there are 17 genes (from UBP1 to UBP17) encoding different
ubiquitin-specific processing proteases and thus potential candi-
dates to deubiquitylate PCNA. To identify ubiquitin proteases that
might play a role in the reversal of PCNA ubiquitylation, we
examined PCNA ubiquitylation patterns of Saccharomyces cerevisiae
strains lacking individual ubiquitin proteases. To detect modified
forms of this sliding clamp we used a polyclonal rabbit antibody
that specifically detects PCNA in S.cerevisiae cell extracts
(Figure 1A). As shown in Figure 1B, ubp10D mutant cells
accumulated di-ubiquitylated PCNA forms, a phenotype consis-
tent with defects in deubiquitylation of this sliding clamp. This
phenotype (the accumulation of ubiquitylated PCNA) was also
observed in cells expressing a version of Ubp10 that lacks catalytic
activity (ubp10C371S) (see later), a catalytic inactive form previously
described [25]. We also found that the ubiquitylated PCNA forms
accumulated in ubp10D mutant cells were covalent modifications
on Lysine 164 of the sliding clamp (Figure 1C and Figure S1).
Ubp10 and Ubp8 are the ubiquitin proteases that remove
monoubiquitin from histone H2B [24,25]. Although these H2B-
deubiquitylating enzymes have distintc functions [26], deletion of
both UBP8 and UBP10 results in a synergistic increase in H2B
ubiquitylation levels suggesting that they regulate the global
balance of that histone modification [24,25]. Thus, even though
we detected normal levels of PCNA modifications in ubp8Dmutant
cells, we tested whether or not deletion of UBP8 in a ubp10D
mutant further increased PCNA ubiquitylation levels. We found
that the accumulation of ubPCNA was specific to ubp10D (Figure
S2).
Cells lacking UBP10 accumulate mono- and di-
ubiquitylated PCNA in response to DNA damage and
replicative stress
It has been shown that the ubiquitylation of PCNA is restricted
to, although separable from, S-phase [7,27,28]. Under physiolog-
ical circumstances active DNA replication forks are required for
PCNA ubiquitylation [27]. In fact, PCNA ubiquitylation is
induced by chemicals that cause disruptive covalent modifications
of DNA, blocking replication and that involve the accumulation of
single-stranded DNA. Thus, in S. cerevisiae, PCNA is ubiquitylated
during S-phase in response to the detection of DNA lesions caused
by methyl methane sulfonate (MMS), hydroxyurea (HU), 4-
nitroquinoline 1-oxide (4-NQO), UV light, hydrogen peroxide
(H2O2) and ionizing radiation [27]. We therefore wondered
whether ubp10D mutants accumulate more ubiquitylated PCNA
than wild-type cells in response to all these types of inducers. As
shown for MMS, HU, 4-NQO and UV light (Figure 1D and 1E),
we found that ubp10D mutant cells accumulated increased levels of
ubiquitylated PCNA as compared to control wild-type cells. This
observation indicates that in vivo Ubp10 modulates the level of
DNA damaged-induced PCNA ubiquitylation.
Overproduction of Ubp10 reverts PCNA ubiquitylation
and sensitizes cells to MMS–induced DNA damage
The increased levels of PCNA ubiquitylation observed in
UBP10 mutant cells suggested that Ubp10 could be a potential
candidate for the deubiquitylation of PCNA in vivo. We therefore
analyzed the ability of Ubp10 to counteract MMS-induced
ubiquitylation of PCNA when overproduced. We examined
PCNA ubiquitylation in strains in which expression of UBP10
was regulated by the strong galactose-inducible GAL1,10 promot-
er. Exponentially growing cultures were treated with MMS. Then,
the expression of UBP10 was either induced or repressed by
adding galactose or glucose, respectively. Samples were taken at
regular intervals and processed for Western analysis of PCNA
ubiquitylation (Figure 2A). Overexpression of UBP10 resulted in
rapid reversion of PCNA ubiquitylation, consistent with a role as
an ubiquitin-specific processing protease for PCNA. Interestingly,
Author Summary
DNA damage is a major source of genome instability and
cancer. A universal mechanism of DNA damage tolerance
is based on translesion synthesis (TLS) by specialized low-
fidelity DNA polymerases capable of replicating over DNA
lesions during replication. Translesion synthesis requires
the switch between replicative and TLS DNA polymerases,
and this switching is controlled through the ubiquitylation
of the proliferating-cell nuclear antigen (PCNA), a proces-
sivity factor for DNA synthesis. It is thought that DNA
polymerase switching is a reversible process that has a
favorable outcome for cells in the prevention of irrevers-
ible DNA replication forks collapse. However, the low-
fidelity nature of TLS polymerases has unfavorable
consequences like the increased risk of mutations opposite
to DNA lesions. Here we identify Ubp10 as an enzyme
controlling PCNA deubiquitylation in the model yeast S.
cerevisiae. The identification of Ubp10 is a first step that
will allow us to understand its biological significance and
its potential role as part of a safeguard mechanism limiting
the residence time of TLS DNA polymerases on replicating
chromatin in eukaryotes.
Ubp10 Deubiquitylates ubPCNA
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both mono- and di-ubiquitylated PCNA forms rapidly disappeared
in cells overexpressing UBP10, suggesting that Ubp10 also
deubiquitylates di-ubPCNA forms. These deubiquitylation events
depended on the protease activity of Ubp10 as a catalytically
inactive Ubp10C371S mutant form was unable to deubiquitylate
PCNA in vivo in similar conditions (Figure 2B). We have also
observed that Ubp10 overproduction reverts ubiquitylation of
PCNA induced by treatments with HU, 4-NQO and UV
radiation. In summary, these experiments indicate that overex-
pression of catalytically active Ubp10 can deubiquitylate ubPCNA
in vivo. Importantly, this in vivo reaction did not require any other
UBP gene, as active Ubp10 did deubiquitylate ubPCNA in any
single UBP1-17 deletion (Figure S3).
Yeast PCNA mutants lacking the ubiquitin/SUMO-conjuga-
tion site K164 or mutated in the PCNAK164-E3 ubiquitin ligase
Rad18 are hypersensitive to MMS (and other DNA damaging
agents) because the ubiquitylation of this K164 amino acid residue
is critical to tolerate DNA damage [29]. It is then reasonable to
predict that the overexpression of the K164-ubPCNA ubiquitin-
specific protease will counteract Rad18 activity and induce MMS
hypersensitivity. Therefore, we exposed UBP10-overexpressing
cells to the chronic presence of the alkylating chemical and found,
Figure 1. Cells lacking UBP10 accumulate mono- and di-ubiquitylated PCNA in response to DNA damage and replicative stress. (A) A
polyclonal rabbit antibody that specifically detects PCNA forms in yeast cell extracts. Immunoblot analysis with (affinity purified) rabbit a-PCNA
antibody of TCA-protein extracts from wild-type, rad18D (unable to ubiquitylate PCNA), pol30K164R (unable to ubiquitylate or SUMOylate PCNA),
mms2D (unable to biubiquitylate PCNA) and siz1D (unable to SUMOylate PCNA) cells treated 90 minutes with 0.020% MMS and resolved in 10% or
12% polyacrylamide gels (as indicated), note that right lane of the 10% gel correspond to wild-type cells treated with 0.3% MMS (conditions where
only SUMOylated PCNA forms are detected). (B) Di-ubiquitylated PCNA accumulation in MMS-treated single ubp1 to ubp17 deletions in S.cerevisiae.
Graph of di-ubiquitylated PCNA accumulation in 0.020% MMS-treated single UBP1-17 deletions in S.cerevisiae. Wild-type and single mutant cells
exponentially grown at 30uC were treated 60 minutes with 0.020% MMS. TCA-cell extracts were analyzed for PCNA ubiquitylation by Western blot,
quantitated and plotted. Average values from three independent assays are plotted. (C) Immunodetection of ubiquitylated forms of PCNA in wild-
type, ubp10D, pol30K164R and ubp10D pol30K164R TCA-cell extracts to show that UBP10 mutant cells accumulate K164 mono-ub and di-ubPCNA forms.
Immunodetection of mono-ubiquitylated (D) and di-ubiquitylated PCNA (E) in wild-type and ubp10D cells treated with 0.020% MMS, 200 mM HU,
0.2 mg/ml 4-NQO and 100 J/m2 UV-light (as indicated). Rad53 phosphorylation was used to test checkpoint activation upon treatments.
doi:10.1371/journal.pgen.1002826.g001
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as predicted, that high levels of expression of the catalytically
active form of this ubiquitin protease (but not the inactive
Ubp10C371S form) induced hypersensitivity to MMS (Figure 2C).
Significantly, this effect was specifically related to high levels of
expression of Ubp10 because overexpression of any other UBP
gene neither sensitize cells to MMS nor induce PCNA deubiqui-
tylation in vivo (Figure S4). Regarding UBP10 overexpression, two
additional and testable predictions can be made, first, the
hypersensitivity to MMS should depend on the PCNA lysine
164 modification. To test this prediction we used a simple epistasis
analysis to determine the order of function of the POL30 and
GAL1,10: UBP10 (Figure S5). We have indeed found that POL30 is
epistatic to GAL1,10: UBP10 indicating that the MMS-sensitivity
of Ubp10 overproduction depends on the PCNA lysine 164
modification. Second, given that mono-ubiquitylation of the K164
residue of PCNA is in principle important to enhance its
interaction with mutagenic TLS polymerases, it is plausible to
predict that the mutagenesis frequency of cells overexpressing
UBP10 should be reduced as compared to wild-type cells. We have
found that this is the case (Figure S6).
Catalytically active Ubp10 deubiquitylates PCNA in vivo
independently from histone H2B deubiquitylation
The above observations correlated the enzymatic activity of
Ubp10 with PCNA deubiquitylation in vivo. However, these effects
may depend on deubiquitylation of histone H2B, as Ubp10
Figure 2. GAL1-driven overproduction of UBP10 reverts PCNA ubiquitylation in response to DNA damage. (A) Time-course analysis of
active GST-Ubp10 induction. An asynchronously growing culture of GAL1,10:GST-UBP10, incubated in raffinose as unique carbon source, was
incubated 30 minutes in the presence of 0.02% MMS. Expression of GST-Ubp10 was either repressed by adding glucose (GAL OFF) or induced with
galactose (GAL ON) in the continuous presence of the alkylating chemical (as described). Samples were taken at indicated intervals and processed for
immunodetection of modified PCNA forms, PCNA, GST-Ubp10 and Rad53. Ponceau staining of the blotted protein extracts is shown. Mono-
ubiquitylated PCNA was quantitated, normalized and plotted. (B) Catalytically active Ubp10 reverts PCNA ubiquitylation in vivo. Immunodetection of
ubiquitylated and di-ubiquitylated PCNA forms in wild-type cells and in cells reppressed (GAL OFF) or induced (GAL ON) for GST-Ubp10 or GST-
Ubp10CS expression, after a 90 minutes treatment with 0.020% MMS. TCA-obtained cells extracts were processed for immunoblotting with a-PCNA
and a-GST antibodies. Ponceau staining of the blotted protein extracts is shown for loading control. (C) Ectopic expression of a catalytically active
Ubp10 ubiquitin protease hypersensitizes cells to MMS-induced DNA damage. Ten-fold dilutions of equal numbers of cells of wild-type, GAL1,10:GST-
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deubiquitylates K123 ubH2B [24,25]. In order to understand
whether deubiquitylation of H2B and PCNA were independent
from each other, we repeated our overexpression analysis in a
bre1D mutant background. Bre1 is the E3 ubiquitin ligase that
ubiquitylates histone H2B in yeast cells, thus, deletion of the BRE1
gene impedes H2BK123 ubiquitylation [30,31]. Importantly, BRE1
deleted cells are viable, providing a tool to answer the question. As
shown in Figure S7, overproduction of catalytically active Ubp10
reverts PCNA ubiquitylation and hypersensitize cells to MMS
similarly in wild-type and bre1 mutant cells. These results indicate
that Ubp10-dependent PCNA deubiquitylation is functionally
separable from ubiquitylation of histone H2B.
Ubp10 is required for rapid PCNA deubiquitylation after
MMS–induced DNA damage
MMS modifies guanines and adenines to methyl derivatives
causing DNA base mispairing, inducing DNA damage and slowing
down progression of DNA replication forks during S-phase [32–35].
MMS also induces ubiquitylation of PCNA in all model organisms
tested to date (reviewed in [4]). To further study the role of Ubp10
in the modulation of PCNA ubiquitylation in yeast, we analyzed by
Western blot samples taken at regular intervals from wild-type cells
treated for 60 minutes with the alkylating chemical and compare
them to samples taken from UBP10 mutant cells in similar
conditions (Figure S8). As observed in the Figure S8, wild-type
cells ubiquitylate PCNA after the MMS treatment and then actively
deubiquitylate the sliding clamp in such way that 45 minutes after
the release from the drug treatment ubiquitylated PCNA was barely
detectable. In contrast UBP10 deleted cells maintained steady state
levels of ubiquitylated PCNA throughout the experiment, suggest-
ing that these cells lack the appropriate enzyme involved in the
deubiquitylation of the modified clamp.
PCNA interacts in vivo with Ubp10
Having observed that deletion and overexpression phenotypes
of Ubp10 were consistent with the hypothesis that this ubiquitin-
specific protease deubiquitylates PCNA in yeast, we next
addressed whether Ubp10 and PCNA interact in vivo, as expected
for an enzyme-substrate complex.
Addition of single ubiquitin residue to Lys164 of PCNA in yeast
is controlled by the E2–E3 complex Rad6–Rad18 during S-phase
[7,28]. Accordingly, the Rad6–Rad18 enzyme complex and its
substrate PCNA interact in vivo, as has been observed by yeast two-
hybrid analyses [29]. We speculated that Ubp10 could form a
complex with PCNA in a Rad18 dependent manner, as it has been
described previously for other E3-ubiquitin ligases [36–38]. If this
were true, it could be predicted that these interactions might be
detected by co-immunoprecipitation analysis. In particular, we
were interested in determining a possible in vivo PCNA-Ubp10
interaction at endogenous levels of both proteins. Since we used a
C-terminally myc-tagged Ubp10 strain we carefully checked
growth rate, gene expression levels, PCNA and histone H2B
deubiquitylation and found no differences with untagged wild-type
controls, as shown for PCNA (Figure S9). By Western and co-
immunoprecipitation assays, we found that Ubp10-myc is stable
upon exposure to DNA damage and that Ubp10 binds PCNA
throughout the cell cycle and in response to MMS-induced DNA
damaged (Figure S9). We then studied Ubp10-PCNA interaction
in wild-type and rad18D mutant cells and observed that Ubp10
and PCNA interact in vivo in a Rad18 semi-dependent manner
(Figure 3A and 3B). We next tested Ubp10 and Rad18 interaction
and found that Rad18 can associate in vivo with Ubp10 both in
undamaged and exogenously DNA-damaged cells (Figure S10).
These results suggest that in yeast cells Ubp10, PCNA and Rad18
could form a complex. These findings, particularly those related to
PCNA and Ubp10 interaction, strongly support the hypothesis
that Ubp10 is an ubiquitin-specific protease that deubiquitylates
PCNA in yeast cells.
Deletion of UBP10 results in a net increase in the
interaction of Rev1 with PCNA
In S.cerevisiae, REV1 encodes a deoxycytidyltransferase required
for the bypass of abasic sites in damaged DNA. Rev1p forms a
complex with the subunits of DNA polymerase f Rev3 and Rev7,
which are involved in error-prone lesion bypass as yeast TLS DNA
polymerases [14,39]. Furthermore, it has been shown that yeast
Rev1 interacts with, and its activity is stimulated by, PCNA [40,41].
Therefore, we reasoned that the accumulation of mono-ubiquity-
lated PCNA observed in UBP10 mutant cells could lead to an
increased interaction between PCNA and TLS DNA polymerases,
including the TLS-interacting Rev1 protein. We tested this
possibility by co-immunoprecipitation assays in vivo using strains
carrying myc-tagged Rev1 and either wild-type or C-terminal
FLAG-tagged PCNA. We detected the reported interaction
between the sliding clamp PCNA and the deoxycytidyltransferase
Rev1 in the wild-type strain and, importantly, it was increased in
cells lacking a functional Ubp10, as predicted (Figure 4A and 4B).
We also found that this increase observed in ubp10D mutant cells
was dependent on the PCNA lysine 164 modification (Figure S11).
Interestingly, we found that the sliding clamp co-immunoprecipi-
tated Rev1 from asynchronous or MMS-damaged cell cultures
(Figure 4C and Figure S12). If this enhacement (in Rev1-PCNA
interaction) observed in ubp10Dmutant cells is due to an increase in
the ubiquitylation of PCNA, it would be expectable to detect
ubiquitylated PCNA in undamaged cells. To our knowledge,
detection of ubPCNA in undamaged budding yeast cells remains
elusive. However, by immunoprecipitating the sliding clamp from
POL30-FLAG tagged cells, although weakly, we detected ubiquity-
lated PCNA in asynchronous cultures of exponentially growing
wild-type and UBP10 mutant cells and indeed found that the
mutant accumulated ubiquitylated PCNA (Figure S13). This
observation supports the correlation between the increase in
ubPCNA and the enhancement of Rev1-PCNA interaction in
undamaged cells. Finally, we did not observe PCNA-Rev1
interaction in G1 synchronized cells, even though the Rev1 protein
was present in the cell extracts (Figure 4B, 4C and Figure S12).
We next analyzed chromatin-associated Rev1 foci and found that,
in agreement with the co-immunoprecipitation results, ubp10D
mutant cells had increased numbers of Rev1 foci (mean6s.d.: wild
type, 16.6468.42; ubp10D, 20.47610.24). Remarkably, a detailed
analysis revealed a significant increment in nuclei with high numbers
of Rev1 foci in UBP10 mutant cells (Figure 4D). In theory, the
observed increased interaction between PCNA and Rev1 in UBP10
deleted cells could be suggestive of a greater TLS activity on
replicating chromatin that would result in increased mutagenic rate.
Therefore, we next monitored the forward mutation rate to
canavanine resistance [42] in undamaged or MMS-damaged ubp10D
mutant cells. However, we found no statistically-significant differenc-
es in the mutagenic rate when compared to that of wild-type cells
(Figure S14), indicating that increasing levels of PCNA ubiquitylation
has no observable impact in the frequency of mutation.
Analysis of the interaction of Rev3 and Rev7 with PCNA
in cells deleted for UBP10
The Rev1-Rev3/Rev7 complex formation has been succesfully
tested in yeast [43,44]. However, having shown that mutation of
UBP10 enhances Rev1 interaction with PCNA but does not
Ubp10 Deubiquitylates ubPCNA
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Figure 3. PCNA interacts in vivo with Ubp10. (A) The sliding clamp PCNA and Ubp10 specific-ubiquitin protease interact physically in vivo. Co-
immunoprecipitation assay showing physical interaction between Ubp10-myc and FLAG tagged PCNA. PCNA-FLAG was immunoprecipitated from
formaldehyde-crosslinked protein extracts (see methods) both from untreated or 0.020% MMS-treated cells, blots were incubated with a-myc (to
detect Ubp10) or a-FLAG (to detect PCNA). The immunoblots shown are those from untreated cells (a similar result was obtained with MMS-treated
cells). As indicated the strains used in this assays were UBP10-myc POL30-FLAG and UBP10-myc POL30-FLAG rad18D. Immunoprecipitated Ubp10-myc
was quantitated, normalized and plotted. Each immunoprecipitation experiment was repeated three times to gain an estimate of error. (B) Co-
immunoprecipitation assay showing physical interaction between Ubp10-myc and PCNA. PCNA was immunoprecipitated both from untreated or
0.020% MMS-treated cells, blots were incubated with a-myc (to detect Ubp10) or a-PCNA. The immunoblots shown are those from MMS-treated cells
(a similar result was obtained with untreated cells). As indicated the strains used in this assays were UBP10-myc and UBP10-myc rad18D.
Immunoprecipitated Ubp10-myc was quantitated, normalized and plotted. Note that in our experiments we detect Ubp10 interacting with
unmodified PCNA (or unmodified PCNA-FLAG).
doi:10.1371/journal.pgen.1002826.g003
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increase mutation frequency (and in order to explain this
discrepancy), we wondered whether the Rev3/Rev7 (DNA
polymerase f) interaction with PCNA was regulated in a different
way than the observed for Rev1 in ubp10D yeast mutant cells. In
order to test this hypothesis, we first analysed Rev3-PCNA
interaction in wild-type and ubp10D cells (Figure 5A). By co-
immunoprecipitation assays, we found that Rev3, the catalytic
subunit of pol zeta, interacts with PCNA in wild-type and ubp10D
mutant strains. We also observed that the amount of Rev3 co-
immunoprecipitated with PCNA was similar in both strains either
in asynchronous cultures or when cells were treated with MMS.
We nex studied the interaction of PCNA with the accessory
subunit of DNA polymerase f Rev7 (Figure 5B and 5C). Rev7
stimulates the activity of Rev3 [14] and is required for mutagenesis
induced after DNA damage in such a manner that deletion of
REV7 decreases mutagenesis frequency in yeast [45]. Significantly,
in our co-immunoprecipitation assays we did observe that the
interaction of PCNA with Rev7 was greatly reduced in cells
deleted for UBP10 supporting an explanation for the wild-type-like
mutagenesis frequency observed in them.
Cells lacking Ubp10 accumulate mono- and di-
ubiquitylated forms of PCNA in response to HU-induced
DNA replication blocks
The evidence presented up to here indicate that the activity of
Ubp10 is required for reverting PCNA ubiquitylation but does not
Figure 4. Increased Rev1–PCNA interaction in cells deleted for UBP10. (A) Co-immunoprecipitation assay showing physical interaction
between Rev1-myc and PCNA. PCNA was immunoprecipitated from 0.020% MMS-treated cells, blots were incubated with a-myc (to detect Rev1) or
a-PCNA. The immunoblots shown are those from MMS-treated cells (a comparable result was obtained with untreated cells). As indicated the strains
used in this assays were REV1-myc and REV1-myc ubp10D. Immunoprecipitated Rev1-myc was quantitated, normalized (to immunoprecipitated PCNA)
and plotted. In (A) as well as in (C), the average and standard deviation values obtained from three independent experiments are plotted. (B) Co-
immunoprecipitation assay showing physical interaction between Rev1-myc and PCNA-FLAG. PCNA-FLAG was immunoprecipitated (from protein
samples crosslinked with formaldehyde, see methods) from asynchronously growing or a-factor blocked cells (as indicated), blots were incubated
with a-myc (to detect Rev1) or a-FLAG (to detect PCNA). As indicated the strains used in this assays were REV1-myc POL30-FLAG and REV1-myc POL30-
FLAG ubp10D. (C) Plots of PCNA-FLAG-co-immunoprecipitated Rev1-myc from untreated and 0.02% MMS-treated cells. Rev1-myc samples were
quantitated and normalized to immunoprecipitated PCNA-FLAG. Quantitation is shown in bar diagrams. (D) Increased number of chromatin-
associated Rev1 foci in MMS-treated UBP10 mutant yeast cells. Spread nuclei of wild-type and ubp10D strains carrying REV1-myc tagged were stained
with DAPI (blue) and anti-myc antibodies (red). Cells were treated with 0.03% MMS for 1 h. The nuclei were classified in three categories according to
the number of Rev1 foci. Representative ubp10D spread nuclei of each class and quantitation of wild-type and ubp10D nuclei are shown. 47 nuclei
were scored for each strain.
doi:10.1371/journal.pgen.1002826.g004
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addesss when Ubp10-mediated PCNA deubiquitylation takes
place during the cell cycle. Therefore, we were next interested in
understanding whether deubiquitylation of PCNA occurs during
S-phase. Through the depletion of nucleotides, the drug hydroxy-
urea (HU), an effective ribonuclease reductase inhibitor, causes an
early S-phase arrest in S.cerevisae cells [46] and induces ubiquityla-
tion of PCNA [27], thus, providing a way to study the regulation
of PCNA ubiquitylation in the presence of stalled DNA replication
forks. In this scenario, we compared PCNA ubiquitylation in wild-
type and ubp10D mutant cells (Figure 6). Cells in logarithmic
growth at 30uC were synchronyzed with a-factor and then
released in 0.2M HU at the same temperature and samples (taken
at regular intervals) processed for Western analysis of PCNA. We
used as S-phase markers PCNA SUMOylation [29], Rad53
activation [35] and Clb5 accumulation [47–50]. As recently
described [7,27,28], we detected PCNA ubiquitylation as soon as
cells entered S-phase, coincident with the appearance of PCNA
SUMOylation, Rad53 activation (in response to HU) and Clb5
accumulation (Figure 6C). Under the chronic presence of HU, in
wild-type cells PCNA ubiquitylation reached a maximum
40 minutes after the release from the pheromone arrest and then
started to decline with stalled DNA replication forks as judged
from all markers, including DNA content analysis by FACS. The
timing of PCNA ubiquitylation observed here correlates well with
the recently described timing of association of Rad18 with
replicating chromatin in HU treated cells [27]. The decrease in
ubPCNA observed in wild-type cells was somewhat surprising;
however, it does indicate that yeast cells down-regulate the
modification of the clamp during S-phase. In contrast, cells lacking
Ubp10 activity, even though they progressed into S-phase later or
more slowly than controls (Figure 6B and 6C), accumulated
increased amounts of mono and di-ubiquitylated forms of the
clamp that remained high all throughout the synchronous
experiment (see bar plot for ubPCNA in Figure 6C). The analysis
of ubp10D mutant cells is consistent with the idea that this
ubiquitin-specific protease down-regulates PCNA ubiquitylation
during S-phase and suggest that Ubp10 is a major deubiquitylating
enzyme for ubPCNA in budding yeast cells (see model in Figure 7).
Discussion
In this work we present clear evidence indicating that Ubp10
controls PCNA deubiquitylation in S. cerevisiae. Ubp10 has a well
established role as an ubiquitin-specific protease of ubH2B, a role
related to gene-silencing (at telomeres, rDNA and cryptic mating
type loci), together with Ubp8, the SAGA-associated ubH2B
deubiquitylase involved in gene expression [24,25]. Thus, in
combination Ubp8 and Ubp10 regulate the global balance of
ubH2B [24,25]. In addition to this role, here we present results
supporting that Ubp10 is an important ubiquitin-specific protease
also in removing ubiquitin from ubPCNA in budding yeast. Our
observations that wild-type cells deubiquitylate ubPCNA in
response to the alkylating chemical MMS or under the chronic
presence of HU show that there exists an active control to revert
PCNA ubiquitylation in S.cerevisiae yeast cells. Moreover, our
experiments with ubp10C371S mutant strains indicate that such
control depends on the catalytic activity of Ubp10/Dot4.
UBP10 deleted cells or cells carrying a catalytically inactive form
of Ubp10 accumulate ubPCNA, a phenotype consistent with the
idea that in vivo Ubp10 is the protease that removes ubiquitin from
ubiquitylated PCNA. In agreement with this role, overexpression
of active Ubp10 reverts PCNA ubiquitylation and hypersensitizes
cells to MMS. Moreover, Ubp10 and the sliding clamp PCNA
interact in vivo as expected from the formation of and enzyme-
substrate complex. Importantly, the function of Ubp10 as
ubPCNA ubiquitin-specific protease is separable from histone
H2B ubiquitylation, as Ubp10 deubiquitylates ubPCNA in cells
lacking Bre1, the E3 ubiquitin ligase that in complex with Rad6
monoubiquitylates histone H2BK123 [31,51]. However, the
ubPCNA and ubH2B deubiquitylation roles of Ubp10 might be
functionally related. One interesting hypothesis is that Ubp10-
dependent deubiquitylation of ubPCNA and ubH2B are insepa-
rable functions. It is arguable that Ubp10 might modulate both
replication bypass and histone modification in order lo leave the
epigenetic marks unaltered during DNA replication. In fact, it has
been inferred from DT40 chicken cells defective in Rev1 that this
TLS-associated deoxycytidyl transferase is involved in replication
of G4-structured DNA regions and, as a consequence of it, in
leaving intact their histone methylation epigenetic marks [52].
Since here we report a functional link between Rev1, PCNA,
Rad18 and Ubp10, it is reasonable to surmise that Ubp10 would
modulate PCNA ubiquitylation and (the maintenance of) histone
imprinting during replication. These modulatory roles are also
consistent with the fact that the modulator (Ubp10) might form
part of the complexes (PCNA, Rad6-Rad18, Rad6-Bre1) involved
in both actions.
An important observation presented in this work is that Ubp10
is able to remove mono-ubiquitin as well as di-ubiquitin from
PCNA in vivo, suggesting that this ubiquitin protease enzyme may
be crucial for keeping TLS polymerases in check as well as for
down-regulating the error-free bypass. Thus, a single deubiquity-
lating enzyme might downregulate both branches of the tolerance
pathway to DNA damage in budding yeast.
Where does PCNA deubiquitylation take place? The answer to
this simple question is not necessarily trivial, since the localization
Ubp10 might be a point of interest for future analysis. Initial
studies in formaldehyde-fixed cells suggested that Ubp10 localizes
primarily at the nucleus [53]; however, using in vivo studies of
Figure 5. Analysis of Rev3-PCNA and Rev7-PCNA interactions in cells deleted for UBP10. (A) Rev3 (DNA polymerase f catalytic subunit)
interacts with PCNA similarly in wild-type and ubp10D cells. Co-immunoprecipitation assay showing physical interaction between Rev3-myc and
PCNA-FLAG. PCNA-FLAG was immunoprecipitated from asynchronously growing or 0.02% MMS-treated cells (as indicated), blots were incubated
with a-myc (to detect Rev3) or a-FLAG (to detect PCNA). As indicated the strains used in this assays were REV3-myc POL30-FLAG, REV3-myc POL30-
FLAG ubp10D and single tagged POL30-FLAG or REV3-myc controls. Whole cell extracts (WCE) and mock Ip controls are also shown as indicated. (B)
The interaction of PCNA with Rev7 (an accessory subunit of DNA polymerase f) is reduced in cells deleted for UBP10. Co-immunoprecipitation assay
of Rev7-myc and PCNA-FLAG. PCNA-FLAG was immunoprecipitated from asynchronously growing or 0.02% MMS-treated cells (as indicated), blots
were incubated with a-myc (to detect Rev7) or a-FLAG (to detect PCNA). As indicated, the key strains used in this assays were REV7-myc POL30-FLAG
and REV7-myc POL30-FLAG ubp10D. Appropriate single tagged, input (WCE) and mock Ip controls are shown. (C) Deletion of UBP10 alters the
interaction of PCNA with Rev7. To assure that deletion of UBP10 reduced significantly Rev7-PCNA interaction, UBP10 was deleted in the REV7-myc
POL30-FLAG strain used in B. Five different REV7-myc POL30-FLAG ubp10D deletion strains and a REV7-myc POL30-FLAG control were used in the co-
immunoprecipitation analysis. PCNA-FLAG was immunoprecipitated from asynchronously growing cells, blots were incubated with a-myc (to detect
Rev7) or a-FLAG (to detect PCNA). The strains used in this assays were either REV7-myc POL30-FLAG (1) or REV7-myc POL30-FLAG ubp10D (2a, 2b, 2c, 2d
and 2e). Input whole cell extracts (WCE) and mock Ip controls are shown. Note that similar amounts of Rev7 are present in whole cell extracts of REV7-
myc POL30-FLAG (1) and REV7-myc POL30-FLAG ubp10D (2c) cells.
doi:10.1371/journal.pgen.1002826.g005
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Ubp10-GFP as well as immunofluorescence analysis of Ubp10-
myc on nuclear spreads, we have found that Ubp10 localizes
mainly in the rDNA-containing nucleolar region (our own
unpublished observations). Thus, does Ubp10 localize permanent-
ly to the nucleolus? ChIP evidence has confirmed rDNA loci,
telomeres and cryptic mating type loci localization [24,25,54] so
that Ubp10-dependent deubiquitylation of ubH2B should take
place there. Deubiquitylation of ubPCNA may follow a more
dynamic pattern (as DNA replication forks move during ongoing
replication). Alternatively, and more simply, an undetected
fraction of Ubp10 might be permanently located out of the
nucleolus or might be released from this nuclear compartment to
control the deubiquitylating processes during S-phase and
postreplication repair. Future studies will address these alterna-
tives.
As in yeast cells, PCNA ubiquitylation is required for
mammalian cell survival after UV irradiation, HU or MMS
treatment [55]. In human cells Usp1 deubiquitylates PCNA as well
as the Fanconi’s anaemia protein FANCD2 [19,56–58]. It has
been shown that human Usp1 incessantly deubiquitylates
ubPCNA in the absence of DNA damage [18]. Upon UV light-
induced DNA damage, Usp1 is (auto)proteolysed, such that PCNA
becomes ubiquitylated [18,19]. Our work has uncovered several
differences in the regulation of PCNA deubiquitylation between
yeast and human cells. First, we observed that UBP10 deleted yeast
cells accumulate ubiquitylated PCNA forms in response to MMS,
HU, UV-light and 4-NQO, suggesting that a single DUB (Ubp10)
may control PCNA deubiquitylation in budding yeast. Second,
Ubp10 appears to deubiquitylate PCNA during S-phase (when the
sliding clamp is modified). Finally, Ubp10 protein levels remained
constant when cells are exposed to DNA damage. Thus, it is
unlikely that a similar Usp1-like autoregulatory mechanism on
yeast Ubp10 ubiquitin protease would exist.
The evidence presented here supported the hypothesis that
Ubp10 deubiquitylates PCNA to limit the residence time of TLS
polymerases on DNA replication forks during S-phase. We tested
this hypothesis directly by studying Rev1-PCNA interaction
because Rev1 serves as a scaffold for the polymerase f, encoded
by REV3 and REV7, for efficient bypass of DNA lesions [59–61].
In agreement with this hypothesis, we found that deletion of
UBP10 resulted in an increased interaction between PCNA and
Rev1 in undamaged and DNA-damaged cells, and that, in turn,
this enhanced interaction resulted in a net increase in Rev1 foci in
chromatin. However, in contradiction with an increased number
of Rev1 foci, we have also found that deletion of UBP10 does not
increase the mutagenic frequency. A conceivable explanation for
Figure 6. Cells lacking Ubp10 accumulate ubiquitylated PCNA forms early during S-phase in response to HU-induced DNA
replication blocks. (A) Experimental design, exponentially growing cultures of wild-type and ubp10D strains were synchronized with a-factor and
then released in 0.2 M HU. Samples were taken at indicated intervals and processed for FACS and Western analysis. (B) FACS analysis showing the
checkpoint-induced S phase arrest of asynchronous wild-type and ubp10D cells during the HU treatment. BI: budding index. (C) Western blot analysis
of PCNA, Rad53, Sic1 and Clb5 protein levels in wild-type and ubp10D cells treated with 0.2 M HU (labeled as wt and 10, respectively). ubPCNA signals
were quantitated and normalized to loading controls. Quantitation is shown in bar diagrams. Whereas ubp10D cells accumulate ubPCNA forms in
response to HU, ubPCNA levels declined after the 40 minutes peak in wild-type cells.
doi:10.1371/journal.pgen.1002826.g006
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this contradiction would be that and additional level of control on
TLS polymerases may exist to regulate their activity. In this
context, one simple possibility is that DNA polymerase f
interaction with replicating chromatin may be hindered in
UBP10 deleted cells. Therefore, to explain the observed discrep-
ancy we studied the interaction of DNA polymerase f subunits
Rev3 and Rev7 with PCNA. Significantly, we have found that
DNA polymerase f accessory subunit Rev7 requires Ubp10 to
fully interact with the sliding clamp PCNA. This observation
explains why ubp10D mutant cells have a wild-type-like mutagenic
frequency and, more importantly, it opens the unexpected
possibility that Rev1 and DNA polymerase f subunits may be
regulated in quite distinct ways regarding their interaction with
PCNA and, thus, with replicating chromatin. Further studies will
be required to test this hypothesis and to study the potencial role of
Ubp10 in modulating DNA polymerase f subunit Rev7 binding to
the sliding clamp PCNA. In summary, our data support that Rev1
interaction with PCNA is modulated by ubiquitylation of PCNA
and, thus, follows the classical regulatory model. Here, we propose
that Ubp10 participates in this modulation through the deubiqui-
tylation of ubPCNA. However, from the observations presented
here we also deduced that Ubp10 may play a direct or indirect role
in regulating Rev7 interaction with the sliding clamp apparently in
a PCNA ubiquitylation independent manner.
It is proper to mention here that the activity TLS-DNA
polymerases activity may be regulated by checkpoint kinases. For
example, it has been shown in budding yeast that Rev1 is
regulated during the cell cycle [62], and that it is phosphorylated
by the Mec1-Ddc2 kinase in response to various types of DNA
damages [63–65]. Thus, in response to DNA damage, yeast cells
would have two different levels of control: first, in modulating the
interaction of PCNA and TLS polymerases, and second, in
regulating TLS polymerases activity and/or stability. A control
mechanism that may be conserved as ATR-mediated phosphor-
ylation of DNA polymerase g is involved in the proper response to
UV-mediated DNA damage in human cells [66].
Figure 7. Model for Ubp10 role on the modulation of PCNA ubiquitylation in S. cerevisiae cells. SUMOylated PCNA progress with the
replisome at replication forks. Detection of bulky lesions on DNA impedes fork progression and induces Rad6/Rad18 ubiquitylation of PCNA;
therefore, it enhances ubPCNA-TLS DNA polymerases interaction or further ubPCNA polyubiquitylation (by the Ubc13/Mms2/Rad5 ubiquitin ligase).
After lesion bypass, Ubp10 deubiquitylates ubPCNA to allow remodelling of the replisome by switching back to replicative DNA polymerases,
resuming rapid and processive DNA replication fork progression.
doi:10.1371/journal.pgen.1002826.g007
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What might be the biological significance of Ubp10-mediated
ubPCNA deubiquitylation in budding yeast? It is tempting to say
that our results suggest that the biological significance of the
control of PCNA deubiquitylation in S.cerevisiae is to prevent
extended residence time of Rev1 in replicating chromatin.
However, there is no unfavorable outcome for yeast cells deleted
for UBP10 as they fail to support a full interaction of (DNA
polymerase f subunit) Rev7 with PCNA and, consequently, they
show a wild-type-like mutagenic frequency. It is true that these
opposite effects on Rev1 and Rev7 suggest the hypothesis that
Ubp10 has a complex role in modulating TLS subunits interaction
with PCNA (and perhaps with replicating chromatin). However,
additional studies will be required to test this hypothesis.
Significantly, it has been reported the functionality in tolerance
of a PCNA mutant form constitutively fused to mono-ubiquitin
[67]. Thus, an alternative interpretation of our results is that
Ubp10-driven deubiquitylation of ubPCNA may not be that
important to tolerate DNA damage in yeast as deletion of UBP10
has no impact in MMS sensitivity nor leads to a mutator
phenotype.
Materials and Methods
General experimental procedures of yeast Molecular and
Cellular Biology were used as described previously [68–71].
Yeast strains, cell culture, and flow cytometry
All the budding yeast used in our studies are listed in Table S1.
Yeast strains were grown in rich YPA medium (1% yeast extract,
2% peptone, 50 mg/ml adenine) containing 2% glucose. For
block-and–release experiments, cells were grown in YPA with 2%
glucose (except where indicated) at 25uC and synchronised with a-
factor pheromone in G1 by adding 40 ng/ml (final concentration,
2.5 hours). Cells were then collected by centrifugation and
released in fresh media in the absence or in the presence of
MMS (or other drugs as indicated). Overexpression experiments
with cells grown in YPA medium with 2% raffinose at 25uC were
conducted by adding to the medium 2.5% galactose (to induce) or
2% glucose (to repress) and further incubating with/without
MMS. For flow cytometry, 107 cells were collected by centrifu-
gation, washed once with water, and fixed in 70% ethanol and
processed as described previously [68,72]. The DNA content of
individual cells was measured using a Becton Dickinson FACScan.
Cells were prepared for flow cytometry as described [72,73].
MMS and drugs sensitivity assays
Exponentially growing or stationary cells were counted and
serially diluted in YPA media. Tenfold dilutions of equal numbers
of cells were used. 10 ml of each dilution were spotted onto YPAD
(2% glucose) or YPAGal (2.5% galactose) plates (always supple-
mented with 50 mg/ml adenine), YPAD or YPAGal plates
containing different concentrations of MMS (Sigma), or HU
(Sigma), incubated at 25uC and scanned. MMS plates were always
freshly made.
Mutagenesis assay
Forward mutation analysis at the CAN1 locus was performed
essentially as described previously [74]. Cells were grown in rich
medium (YPAD or YPAGal) to log phase and MMS (at indicated
concentrations) was added to the half of each culture, which were
further incubated until the saturation point was reached (24 hours
for wild-type, ubp10D and ubp10D rev3D strains in Figure S14 to
48 hours for wild-type, GAL1,10:UBP10, rev3D and GA-
L1,10:UBP10 rev3D strains in Figure S6). Then, cells were plated
on solid medium without arginine but containing 60 mg/ml
canavanine (Sigma) and also in control YPAD plates (for
reference). After 4 days, colonies were counted and the mutagen-
esis frequency (canavanine resistant cells versus total population)
was calculated for each culture. The frequencies provided are
mean values of six or more independent cultures of each indicated
genotype, in at least three independent experiments.
Tagging yeast proteins and gene deletion
Tagged alleles were constructed using the single step PCR-
based gene modification strategy [75]. A similar strategy was used
to generate specific gene deletions. The selection markers used
were KanMX6, which allows selection with geneticin, HphMX4,
which allows selection with hygromicin or NatMX4, which allows
selection with nourseothricin. We used also LEU2 and HIS3
markers (as indicated in Table S1). The resulting genomic
constructions were confirmed by PCR and sequencing. In the
case of tagged alleles, the presence of tagged proteins was
confirmed by Western blot.
Immunoprecipitation, Western blot analysis, and
antibodies
Protein extract preparation for Western analysis. TCA
cell extracts were prepared and analyzed as described previously
[70,76]. SDS-PAGE gels at 15%, 12%, 10% and 7.5% were used
for detection of histone H2B, PCNA (12% and 10%) and Rad53,
respectively.
Protein extract preparation for immunoprecipita-
tions. Soluble protein extracts were prepared basically as
described previously [77]. Cells were collected, washed, and
broken in HB2T buffer using glass beads. The HB2T buffer
contained 60 mM b-glycerophosphate, 15 mM p-nitrophenylpho-
sphate, 25 mM 4-morpholinepropanesulfonic acid (pH 7.2),
15 mM MgCl2, 15 mM EGTA, 1 mM dithiothreitol, 0.1 mM
sodium orthovanadate, 2% Triton X-100, 1 mM phenylmethyl-
sulfonyl fluoride, and 20 mg/ml leupeptin and aprotinin. The
glass beads were washed with 500 ml of HB2T, and the
supernatant was recovered. Protein concentrations were measured
using the BCA assay kit (Pierce). We repeated the immunopre-
ciptation of PCNA or PCNA-FLAG experiments in the presence
of the crosslinking agent formaldehyde (as indicated in Figure
legends), and cell extracts were prepared and then processed as for
ChIP [69,78]. After immunoprecipitation of PCNA or PCNA-
FLAG, tagged proteins were detected by immunoblotting with
specific monoclonal antibodies (the IPs were washed as for ChIP
assays, however, it was mixed with Laemmli buffer before
incubation at 95uC for 30 min to reverse the crosslinking and
denature the eluted proteins). The in vivo interactions described in
the Results section (in particular PCNA with Ubp10 and PCNA
with Rev1) were quantitated from Western analysis of co-
immunoprecipitates. In every case, the experiments were repeated
three times to gain an estimate of error.
Western blotting. Protein extracts and immunoprecipitates
were electrophoresed using SDS-polyacrylamide gels ranging from
7.5 to 15%. For Western blots, 40–80 mg of total protein extracts
from each sample were blotted onto nitrocellulose, and proteins
were detected using a characterized anti-PCNA affinity-purified
polyclonal antibody (1:1500; a generous gift from Dr. Paul
Kaufmann). We also used Clb5, Sic1 and Rad53 antibodies from
Santa Cruz Biotechnology (used as indicated by the supplier), as
well as the 12CA5 monoclonal antibody (Roche Molecular
Biochemicals; 1:500), or the anti-FLAG monoclonal antibody
(1:3000), or the anti-Myc monoclonal antibody (1:3000). Poly-
clonal anti-GST antibody (1:3000) was also used. Horseradish
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peroxidase-conjugated anti-rabbit, anti-goat, or anti-mouse anti-
bodies (as required) and the ECL kit (GE Healthcare) were used.
The antibodies required for immunoblots were used at the
indicated dilutions for Western analysis.
Imaging of cells and citology
Immunofluorescence of nuclear spreads was performed essen-
tially as described previously [71,79]. The anti-myc tag antibody
(clone 4A6, 05-724; Millipore) was used at 1:500 dilution and the
Alexa Fluor 594-conjugated anti-mouse secondary antibody
(A11032; Molecular Probes) was used at 1:200 dilution. Images
were captured using a Nikon Eclipse 90i fluorescence microscope
equipped with an Orca-AG (Hamamatsu) CCD camera and a
PlanApo VC 1006/1.4 objective. Images were processed and
analyzed with the MetaMorph software (Molecular Devices).
Quantification of chromosome-associated Rev1 was performed by
counting the number of Rev1-myc foci in the DAPI-stained area.
Supporting Information
Figure S1 Immunodetection of ubiquitylated forms of PCNA in
yeast TCA-cell extracts to show that UBP10 mutant cells
accumulate K164 but not K127 modified PCNA forms.
Immunoblot analysis with a-PCNA antibody of TCA-protein
extracts from pol30K164R (unable to ubiquitylate or SUMOylate
PCNA at K164), wild-type (wt), pol30K127R (unable to ubiquitylate
or SUMOylate PCNA at K127), ubp10D, ubp10D pol30K127R,
ubp10D, G1 wild-type (wt a-factor), siz1D (unable to SUMOylate
PCNA), mms2D (unable to di-ubiquitylate PCNA), rad18D (unable
to ubiquitylate PCNA), and ubp10D pol30K164R cells treated
90 minutes with 0.020% MMS and resolved in a 12%
polyacrylamide gel, note the presence of a sample from untreated
wild-type cells (8th lane).
(JPG)
Figure S2 ubp10 but not ubp8 mutant cells accumulate
ubiquitylated forms of PCNA in response to MMS-induced
DNA damage. Immunodetection of mono-ubiquitylated
(ubPCNA) and di-ubiquitylated PCNA (Ub2-PCNA) in wild-type,
ubp8D, ubp10D and ubp8D ubp10D cells treated with 0.020% MMS
(as indicated). Ubiquiylated PCNA (ubPCNA) samples were
quantified, normalized to loading controls and plotted. Rad53
phosphorylation is used for testing checkpoint activation upon
MMS-treatment.
(JPG)
Figure S3 GAL1-driven overproduction of UBP10 reverts PCNA
ubiquitylation in any UBP1-17 deletion. Catalytically active
Ubp10 reverts PCNA ubiquitylation in vivo in ubp1D (1D) to
ubp17D (17D) single mutants. Immunodetection of K164-mono-
ubiquitylated PCNA forms in wild-type cells (wt), GAL1-regulated
overexpressing UBP10 cells (wt*) and GAL1-regulated overex-
pressing UBP10 ubp1D (1D) to ubp17D (17D) single mutant cells
either reppressed (OFF) or induced (ON) for Ubp10 overexpres-
sion, after a 90 minutes treatment with 0.020% MMS. TCA-
obtained cells extracts were processed for immunoblotting with a-
PCNA antibody.
(JPG)
Figure S4 Analysis of MMS sensitivity and PCNA ubiquityla-
tion in GAL1-regulated overexpressing UBP1, UBP2, UBP3, UBP4,
UBP5, UBP6, UBP7, UBP8, UBP9, UBP10, UBP11, UBP12,
UBP13, UBP14, UBP15, UBP16 and UBP17 yeast cells. (A) Ten-
fold dilutions of equal numbers of wild-type and GAL1,10-
expressing UBP1, UBP2, UBP3, UBP4, UBP5, UBP6, UBP7,
UBP8, UBP9, UBP10, UBP11, UBP12, UBP13, UBP14, UBP15,
UBP16 and UBP17 cells were incubated at 25uC in the absence or
in the chronic presence of MMS (as indicated) for 72 hours and
photographed. (B) Immunodetection of modified PCNA forms in
wild-type or GAL1,10-expressing UBP1, UBP2, UBP3, UBP4,
UBP5, UBP6, UBP7, UBP8, UBP9, UBP10, UBP11, UBP12,
UBP13, UBP14, UBP15, UBP16 and UBP17 cells, after a
90 minutes treatment with 0.020% MMS. Cells extracts were
processed for immunoblotting with a-PCNA antibodiy. Ponceau
staining of the blotted protein extracts is shown for loading control.
(JPG)
Figure S5 Epistasis analysis of pol30K164R and UBP10 mutant
alleles. (A) Tenfold serial dilutions of wild-type, pol30K164R, ubp10D
and ubp10D pol30K164R cells incubated at 25uC on YPAD plates
with or without the indicated percentages of MMS for 72 hours
and photographed. (B) Tenfold dilutions of equal numbers of
(otherwise isogenic) wild-type, pol30K164R, GAL1,10:UBP10 and
GAL1,10:UBP10 pol30K164R cells incubated at 25uC on YAPD
plates (GAL OFF) to repress GAL1,10-driven UBP10 expression or
YAPGal plates (GAL ON) to induce GAL1-driven UBP10
expression (with or without MMS, as indicated).
(JPG)
Figure S6 Forward mutation analysis in wild-type and GA-
L1,10:UBP10 strains. Canavanine resistance was assayed in wild-
type, GAL1,10:UBP10, rev3D, and GAL1,10:UBP10 rev3D cells
either incubated in galactose to induced UBP10 overexpression
(GAL ON) or in glucose to repress it (UBP10 expression) and
treated with 0.0005% MMS. Note that a low concentration of
MMS was used in this assay because of the hypersensitivity of
UBP10 overexpressing cells (as shown in Figure S4B) to the DNA
alkylating chemical. For the same reason, in these experiments a
56 hours exposure to the chemical was required for cultures to
reach saturation (before plating onto canavanine Petri dishes).
Plots of the resulting forward mutation frequencies are shown.
(JPG)
Figure S7 Catalytically active Ubp10 deubiquitylates PCNA in
vivo independently from histone H2B deubiquitylation. (A) Ten-
fold dilutions of equal numbers of wild-type, ubp10D,
GAL1,10:GST-UBP10, GAL1,10:GST-ubp10C371S, GAL1,10:GST-
UBP10 bre1D and GAL1,10:GST-ubp10C371S bre1D cells were
incubated at 25uC in the absence or the presence of indicated
percentages of MMS for 72 hours and photographed. (B)
Catalytically active Ubp10 reverts PCNA ubiquitylation in vivo
independently from BRE1. Immunodetection of ubiquitylated
PCNA forms in wild-type cells and in cells reppressed (GAL OFF)
or induced (GAL ON) for GST-Ubp10 or GST-Ubp10CS
expression, after a 90 minutes treatment with 0.020% MMS.
Protein extracts were processed for immunoblotting with policlo-
nal a-PCNA antibody. Ponceau staining of the blotted protein
extracts is shown for loading control.
(JPG)
Figure S8 Ubp10 is required for rapid deubiquitylation after
MMS-induced DNA damage. Asynchronously growing cultures of
wild-type and (otherwise isogenic) ubp10D strains were incubated
60 minutes in the presence of 0.02% MMS, washed twice in fresh
(pre-warmed) media and release in YAPD (in the absence of the
alkylating chemical). Samples were taken at indicated intervals and
processed for immunodetection of PCNA forms and Rad53
phosphorylation with a-PCNA and a-Rad53 antibodies. ubPCNA
was quantitated, normalized and plotted.
(JPG)
Figure S9 Analysis of ubp10-myc and ubp10C371S-myc strains. (A)
Asynchronously growing Ubp10-myc cells were blocked in G1
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with a-factor and then released in fresh medium to analyze the
quantity of Ubp10 through the cell cycle; additionally, Ubp10-myc
asynchronous cells were treated with 0.020% MMS 90 minutes,
0.2 M HU 90 minutes or 150 Jm22 UV light. TCA-extracted
protein samples were collected for detection of Ubp10-myc,
PCNA and Rad53. (B) The lack of deubiquiting activity of
Ubp10C371S does not alter the level of the protein, but it causes an
accumulation of ubiquitinated PCNA forms in a similar way than
the deletion of the UBP10 gene. Wild-type (wt), ubp10D,
ubp10C371S-myc (two different clones) and UBP10-myc cells were
treated with 0,02% MMS during 90 minutes and TCA-extracted
protein samples were processed for Western analysis (to detect
Ubp10-myc, PCNA and Rad53), all along with an untreated wt
sample (as indicated). Note that, while UBP10 mutants (ubp10D
and the two ubp10C371S-myc clones) accumulate more mono- and
di-UbPCNA, the ubp10-myc strain has wild-type levels. (C) Ubp10
interacts in vivo with PCNA throughout the cell cycle. Co-
immunoprecipitation assay showing physical interaction between
Ubp10-myc and PCNA. PCNA was immunoprecipitated from
untreated asynchronous (As), a-factor synchronyzed (G1), 30 min-
utes released S-phase (S) or 75 minutes released G2 (G2) cells.
Blots were incubated with a-myc (to detect Ubp10-myc) or a-
PCNA. Appropriate input (WCE) and mock-Ip controls are
shown. (D) Ubp10 interacts in vivo with PCNA in undamaged and
MMS-damaged cells. PCNA was immunoprecipitated from
untreated asynchronous (As) or 0.02% MMS-treated cells. Blots
were incubated either with a-myc (to detect Ubp10-myc) or a-
PCNA. Input (WCE) and mock-Ip controls are shown.
(JPG)
Figure S10 The E3-ubiquitin ligase Rad18 and Ubp10
ubiquitin-specific protease interact physically in vivo. Co-immuno-
precipitation assay showing physical interaction between Ubp10-
myc and Rad18-Ha. Ubp10-myc was immunoprecipitated either
from untreated (Asyn) or 0.02% MMS-treated cells (MMS), blots
were incubated with a-myc (to detect Ubp10) or a-Ha (to detect
Rad18-Ha) as indicated. Appropriate single tagged, input (WCE)
and mock-Ip controls are shown.
(JPG)
Figure S11 Analysis of Rev1-PCNA interaction in pol30K164R
cells in wild-type and ubp10D strains. Co-immunoprecipitation
assay showing physical interaction between Rev1-myc and PCNA
in pol30K164R cells. PCNA was immunoprecipitated either from
untreated or from 0.020% MMS-treated cells, blots were
incubated with a-myc (to detect Rev1) or a-FLAG (to detect
PCNA). As indicated the strains used in this assays were REV1-myc
pol30K164R-FLAG and REV1-myc pol30K164R-FLAG ubp10D. Note
that the relative amount of immunoprecipitated Rev1-myc was
similar in UBP10 or ubp10D cells indicating that Rev1 interacts
with unmodified PCNA (pol30K164R) and that this interaction is not
enhanced in ubp10D mutants.
(JPG)
Figure S12 Co-immunoprecipitation assay showing physical
interaction between Rev1-myc and PCNA-FLAG in MMS-treated
cells. Cell extracts were prepared as for ChIPs (in the presence of
the crosslinking agent formaldehyde, see methods). PCNA-FLAG
was immunoprecipitated from 0.02% MMS-treated cells (459 or
909 samples) or a-factor blocked cells (as indicated), blots were
incubated with a-myc (to detect Rev1) or a-FLAG (to detect
PCNA). As indicated, the strains used in this assays were REV1-myc
POL30-FLAG and REV1-myc POL30-FLAG ubp10D. Note that this
is a representative Western blot of the experiments plotted in
Figure 4C.
(JPG)
Figure S13 Detection of ubiquitylated PCNA forms in asyn-
chronous cultures of wild-type and ubp10D cells by immunopre-
cipitation. Immunoprecipitation of FLAG-tagged PCNA from
asynchronous (Asyn) or 0.02% MMS-treated (MMS) cultures.
Samples were taken from exponentially growing cultures or
90 minutes MMS-treated cultures of POL30-FLAG (wild-type) and
POL30-FLAG ubp10D (ubp10D) strains and processed for immuno-
precipitation with a-FLAG. Immunoblots were incubated with a-
PCNA (to detect unmodified and modified PCNA). Note the
detection of ubiquitylated PCNA in untreated wild-type and
ubp10D cells, and the accumulation of ubiquitylated forms of
PCNA in untreated and MMS-treated ubp10D cells (compared to
wild-type samples).
(JPG)
Figure S14 Forward mutation analysis in wild-type and ubp10D
strains. (A) Canavanine resistance was assayed in ubp10D, ubp10D
rev3D and wild-type control cells either untreated or treated with
0.002% or 0.005% MMS (as indicated). Plots of the resulting
forward mutation frequencies are shown. (B) Viability analysis in
wild-type, rev3D and ubp10D strains. Exponentially growing wild-
type, rev3D and ubp10D strains were exposed the indicated times to
0.05% or 0.2% MMS and test for colony formation. Plots of the
resulting viability test are shown.
(JPG)
Table S1 Yeast strains used in this study.
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